A proven pharmaceutical team developing innovative treatments for psychiatric and neurological disorders.
Psynergy Pharmaceuticals is currently focused on treating autism spectrum disorders.
A proven pharmaceutical team developing innovative treatments for psychiatric and neurological disorders.
Psynergy Pharmaceuticals is currently focused on treating autism spectrum disorders.
Listen to the team discuss the I-Corps@Ohio experience from the summer of 2018.
William S. Messer, Jr., Ph.D.
President and Chief Scientific Officer
Austin Horton
Lead Scientist
Abstract Consolidated memories can become destabilized during reactivation, resulting in a transient state of instability, a process that has been hypothesized to underlie long-term memory updating. Consistent with this notion, relatively remote memories, which are resistant to standard destabilization procedures, are reliably destabilized when novel information (i.e., the opportunity for memory updating) is present during […]
Abstract Studies have demonstrated the presence of allosteric binding sites on each of the muscarinic acetylcholine receptor (mAChR) subtypes. Since most drugs targeting muscarinic receptors bind to the highly conserved orthosteric binding site, they fail to achieve appreciable subtype selectivity. Targeting non-conserved allosteric sites may provide a new way of enhancing selectivity for individual subtypes […]
Abstract Various neurodegenerative diseases and psychiatric disorders are marked by alterations in brain cholinergic function and cognitive deficits. Efforts to alleviate such deficits have been limited by a lack of selective M(1) muscarinic agonists. 5-(3-Ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride (CDD-0102A) is a partial agonist at M(1) muscarinic receptors with limited activity at other muscarinic receptor subtypes. The present […]
